February 13, 2018 / 12:12 PM / 7 months ago

BRIEF-Shire Says Granted Orphan Drug Status For Crohn's Disease Treatment For Children

Feb 13 (Reuters) - Shire Plc:

* SHIRE - U.S. FDA GRANTS ORPHAN DRUG DESIGNATION FOR INVESTIGATIONAL SHP647 FOR TREATMENT OF PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

* SHIRE - HEALTH CANADA GRANTS PRIORITY REVIEW FOR INVESTIGATIONAL LANADELUMAB FOR PREVENTION OF ANGIOEDEMA ATTACKS IN OLDER PATIENTS WITH HEREDITARY ANGIOEDEMA

* SHIRE PLC - PEDIATRIC STUDY PLANS WITH SHP647 ARE CURRENTLY UNDER DISCUSSION WITH HEALTH AUTHORITIES

* SHIRE PLC - HEALTH CANADA REVIEW OF NDS UNDER PRIORITY REVIEW IS EXPECTED TO BE COMPLETED IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below